Sanofi takes its authorised Lovenox generic off US market due to altered market conditions
This article was originally published in Scrip
Executive Summary
The US market for generics of Sanofi’s Lovenox (enoxaparin sodium) injection continues to take some twists and turns – and once again Momenta Pharmaceuticals and partner Sandoz (Novartis) are back in the much envious position as only ones selling a generic enoxaparin in the US, competing solely with the branded Lovenox.